Search the Newsreel

Kenon Holdings (KEN) unit OPC Energy plans NIS 600m Series E bond offering

Kenon Holdings' subsidiary, OPC Energy Ltd., plans to offer NIS 600 million (approximately $202 million) in Series E Bonds on the Tel Aviv Stock Exchange. Institutional investors have already shown strong demand, submitting orders totaling NIS 1.33 billion. The bonds are expected to have …

Salesforce, ServiceNow data targeted in ‘City-Forum’ attacks

Researchers at Reco have identified a new attack campaign, dubbed "City-Forum," targeting user data held in Salesforce and ServiceNow systems. This attack shares similarities with methods used by the ShinyHunters extortion group but employs a novel UI-API layer penetration and a custom toolset. The …

ServiceNow Stock Leads 3 AI Software Picks Built For Enterprise Growth

This article highlights three AI stocks—ServiceNow, Oracle, and Palantir Technologies—that are well-positioned for enterprise growth amid current market conditions. It details each company's operations, market capitalization, and specific AI-related strengths, while also pointing out potential risks like high valuations or significant debt. The analysis …

Menon Bearings Share Price Target 2027 to 2030: Analyst Outlook

ServiceNow Stock And 2 Growth Picks For Lower Rate Expectations

This article highlights three growth stocks—Global-E Online (GLBE), ServiceNow (NOW), and Zscaler (ZS)—that are poised to benefit from cooling US inflation data, record US indices, and softer bond yields, which are shifting market focus back to growth. It details each company's business model, market …

Enovix (ENVX) Q2 2026 Earnings Call: Smart Eyewear Revenue Begins, Pipeline Reaches $183M

Enovix Corporation (ENVX) reported Q2 2026 revenue of $9.0 million, a 21% year-over-year increase, alongside its seventh consecutive quarter of positive gross profit. The company began recognizing revenue from smart eyewear products for a Tier 1 customer and saw its South Korea defense and …

California State Teachers Retirement System Raises Position in NeoGenomics, Inc. $NEO

The California State Teachers Retirement System significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 56.8% in the first quarter, now owning 194,103 shares valued at $1.44 million. This move is reflective of a broader positive sentiment from institutional investors, who collectively own 98.5% …

Lenovo Group (SEHK:992) Faces US ITC DDR5 Patent Complaint

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Lenovo Group (SEHK:992) has been named in a new complaint filed by Netlist at the US International Trade Commission alleging infringement of DDR5 …

ServiceNow, Inc.: Konsensus der Analysten und Kursziel | A1JX4P | US81762P1021

Cenovus Energy Inc. (TSE:CVE) Receives Average Recommendation of "Buy" from Analysts

Fifteen brokerages have given Cenovus Energy Inc. (TSE:CVE) an average "Buy" rating, with a consensus one-year price target of C$43.73. Despite recent insider share sales totaling C$22.2 million, insiders still hold a significant 32.03% ownership. The company reported strong financial performance with C$1.53 in …

Do Wall Street Analysts Like Amphenol Stock?

3d illustration inflation and deflation graph by Deepadesigns via Shutterstock Amphenol Corporation (APH) is a global manufacturer of electrical, electronic, and fiber-optic connectivity products. Headquartered in Wallingford, Connecticut, the company's product portfolio spans connectors, cables, antennas, sensors, and circuit boards for a wide range …

Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA) and PolyPid (PYPD)

This article provides an overview of analyst ratings for three healthcare companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA), and PolyPid (PYPD). BioNano Genomics received a "Buy" rating with a $4.00 price target, while Liquidia Technologies was given a "Hold" rating and a $90.00 price …

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has received a consensus "Buy" rating from seventeen brokerages, with an average 12-month price target of $77.13. The company's stock is currently trading below its recent high, with institutional investors holding a significant 95.45% stake. Recent insider selling has also …

Lenovo Posts Record Quarterly Revenue as AI Push Lifts Profits Despite Accounting Loss

Tenon outlines sacropelvic launches over next six to nine months following FDA 510(k) clearance

Earnings Call Insights: Tenon Medical (TNON) Q2 2026 MANAGEMENT VIEW * "Second quarter revenue was $1.3 million, an increase of 127% over the second quarter last year, and gross profit was $0.8 million, an increase of 232% over the prior year period." (CEO, President …

Tenon Medical earnings missed by $3.95, revenue fell short of estimates

Lenovo's AI Server Pipeline Hits $54 Billion as Adjusted Profit Breaks the Billion Mark

Xenon Pharmaceuticals Director Sold Shares Worth Over $640K

Steven Gannon, a Director at Xenon Pharmaceuticals (XENE), reported the sale of common shares totaling $640,550 on August 11, 2026. The transactions were executed at a weighted-average price of $64.055 per share. Following this sale, Gannon directly holds 1,870 common shares in the company.

Jenoptik AG (JNPKF) (Q2 2026) Earnings Call Highlights: Record Orders and Raised Guidance ...

This article first appeared on GuruFocus. Revenue: Group revenue up 1% year-on-year in H1 2026; excluding currency effects, growth was close to 3%. Order Intake: Group order intake up more than 50% year-on-year in H1 2026. Book-to-Bill Ratio: H1 book-to-bill ratio rose sharply to …

Enovix (ENVX) Stock Drops As Cash Strength Meets Execution Delays

Enovix (ENVX) stock dropped 6% despite strong cash reserves of US$552 million, as Q2 revenue increased by 21% year-on-year to US$9 million with narrowing losses. The company's future hinges on its ability to meet execution milestones for its silicon anode battery technology for smartphones …

Xenon Pharmaceuticals (XENE) Insider Sells 10,000 Shares; Direct

Director Steven Gannon of Xenon Pharmaceuticals (XENE) sold 10,000 shares for $64.06 per share, totaling $640,600, reducing his direct holdings to 1,870 shares. This sale contributes to a broader trend of 13 insider sells and no buys over the past year at Xenon, signaling …

Earnings call transcript: Tenon Medical posts strong growth in Q2 2026

Tenon Medical reported strong revenue growth of 127% year-over-year in Q2 2026, reaching $1.3 million, but still posted a wider net loss of $4.1 million and missed analyst expectations for both revenue and earnings. Despite the financial miss, the company saw significant gross margin …

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

ServiceNow (NYSE:NOW) Trading 1.7% Higher - Should You Buy?

ServiceNow (NYSE:NOW) saw its shares trade up 1.7% to $127.09 after reporting a strong quarter that exceeded expectations, with EPS of $0.90 and revenue of $3.99 billion, prompting an increased annual subscription-revenue outlook. Analysts maintain a "Moderate Buy" consensus with an average price target …

What To Do After Lenovo Posted Q1 Earnings And Jumped By Nearly 20% (OTCMKTS:LNVGY)

Freenome (FRNM) posts $132.6M loss but raises $295.5M via SPAC and PIPE

Freenome Inc. reported a net loss of $132.6 million for the first half of 2026, widening from the previous year, and used $97.1 million in operating cash. Despite these losses and an accumulated deficit of $1.5 billion, the company secured $295.5 million in net …

RideNow Group (RDNW) Stock Profit Rebound Runs Into Debt Doubts

Form 8K Freenome Inc For: 13 August By Investing.com

This article from Investing.com announces that Freenome Inc. filed a Form 8K for August 13. The content of the filing itself is not detailed, as the article primarily serves as a notification of the filing. It mentions the stock symbol FRNM and provides general …

Tenon Medical, Inc. 2Q 2026: Revenue $1.279M, Net loss $(4.05M), EPS $(12.35) — 10-Q Summary

Tenon Medical, Inc. reported its second-quarter 2026 results, showing revenue of $1.279 million, a net loss of $(4.05 million), and a diluted loss per share of $(12.35). Revenue more than doubled year-over-year, driven by increased procedure volumes and the acquisition of the SImmetry+ System. …

Tenon Medical (TNON) lifts SI joint revenue but flags going-concern risk

Tenon Medical (TNON) reported increased revenue for the quarter ended June 30, 2026, reaching $1.3 million, up from $0.6 million a year prior, driven by higher SI joint procedure volumes and contributions from its SImmetry+ system. Despite revenue growth and improved gross margins, the …

10x Genomics Director John R. Stuelpnagel Sells 20,000 Shares in August 2026 SEC Filing

John R. Stuelpnagel, a Director at 10x Genomics, Inc. (NASDAQ:TXG), sold a total of 20,000 shares of Class A Common Stock on August 11, 2026. The sales were conducted in two open-market transactions, with 17,000 shares sold at a weighted average price of $57.5812 …

GCM Grosvenor (GCMG) insider group reports 69.9% beneficial stake via units

An insider group led by Michael Jay Sacks beneficially owns 69.9% of GCM Grosvenor's Class A common stock, totaling 141,672,819 shares as of June 30, 2026. This ownership includes direct shares and Common Units redeemable on a one-to-one basis into Class A shares, held …

Tenon Medical Q2 Revenue Rises 127% to $1.3 Million

Tenon Medical (TNON) reported a significant increase in its Q2 2026 revenue, rising 127% to $1.3 million, with gross profit up 232% to $0.8 million. The company also announced FDA 510(k) clearance for its updated Catamaran SI Joint Fusion System and completed a $4.2 …

Tenon Medical (TNON) posts 127% Q2 2026 revenue growth amid higher net loss

Tenon Medical reported a significant revenue increase of 127% to $1.3 million in Q2 2026, driven by higher surgical procedures and the SImmetry®+ System, alongside an improved gross margin of 64%. Despite this growth, the company's net loss widened to $4.1 million, and it …

Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients

Wellington Management Group LLP and its affiliates have reported a passive ownership stake of approximately 1.47% in Xenon Pharmaceuticals Inc. (XENE) common stock. This stake, representing 1,425,492 shares, is held for advisory clients across various Wellington investment entities, with no single client owning more …

Xenon Pharmaceuticals (XENE) director sells 10,000 common shares at $64

Xenon Pharmaceuticals director Steven Gannon sold 10,000 Common Shares on August 11, 2026, at a weighted-average price of $64.055 per share. The shares were sold in multiple transactions ranging from $64.0517 to $64.078. Following this transaction, Gannon directly holds 1,870 Common Shares of Xenon …